Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8846638 Macrocyclic nucleoside phosphoramidate derivatives

Patent 8846638 was granted and assigned to Enanta Pharmaceuticals on September, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Enanta Pharmaceuticals

Current Assignee

Enanta Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

88466380

Patent Inventor Names

Guoqiang Wang0

Jun Ma0

Yat Sun Or0

Date of Patent

September 30, 2014

Patent Application Number

138970230

Date Filed

May 17, 2013

Patent Citations Received

‌

US Patent 12084473 β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

‌

US Patent 11690860 Treatment of HCV infected patients with cirrhosis

‌

US Patent 11707480 Highly active compounds against COVID-19

‌

US Patent 11975016 2′-substituted-N

‌

US Patent 12006340 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

Patent Primary Examiner

‌

Traviss C Mcintosh, III

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8846638 Macrocyclic nucleoside phosphoramidate derivatives

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API